Lexaria Bioscience Corp
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Lexaria Bioscience's stock with a target price of $9, indicating strong potential for growth.
Financial Health
Lexaria Bioscience is generating strong revenue and cash flow with exceptional profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring LEXX
Next-Generation Drug Delivery Systems
This carefully selected group of stocks represents innovative companies revolutionizing how medications are delivered to patients. Handpicked by our professional analysts, these firms are developing technologies that make treatments simpler, more effective, and user-friendly, creating meaningful investment potential in an evolving healthcare landscape.
Published: July 18, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Delivery tech focus
DehydraTECH is the company’s core asset and explains investor interest; potential licensing revenue exists, though clinical and commercial success are not guaranteed.
Clinical progress matters
Trial results and regulatory updates can materially affect prospects; positive data may drive interest, while setbacks can hurt valuation.
Small‑cap volatility
With a market cap around $20m, Lexaria is a micro‑cap and may show large price swings and liquidity limits—suitability depends on risk tolerance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
